Hémangiome sclérosant du poumon : Questions médicales fréquentes
Nom anglais: Pulmonary Sclerosing Hemangioma
Descriptor UI:D047868
Tree Number:C08.785.520.867
Termes MeSH sélectionnés :
Cholangitis, Sclerosing
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hémangiome sclérosant du poumon : Questions médicales les plus fréquentes",
"headline": "Hémangiome sclérosant du poumon : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hémangiome sclérosant du poumon : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-17",
"dateModified": "2025-04-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hémangiome sclérosant du poumon"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs du poumon",
"url": "https://questionsmedicales.fr/mesh/D008175",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs du poumon",
"code": {
"@type": "MedicalCode",
"code": "D008175",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C08.785.520"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hémangiome sclérosant du poumon",
"alternateName": "Pulmonary Sclerosing Hemangioma",
"code": {
"@type": "MedicalCode",
"code": "D047868",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Weidong Zhang",
"url": "https://questionsmedicales.fr/author/Weidong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Cardiothoracic Surgery, Henan Provincial Chest Hospital (Chest Hospital of Zhengzhou University), Zhengzhou, Henan, China. zhangweidong0371@126.com."
}
},
{
"@type": "Person",
"name": "Tae Wook Kang",
"url": "https://questionsmedicales.fr/author/Tae%20Wook%20Kang",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Dong Ik Cha",
"url": "https://questionsmedicales.fr/author/Dong%20Ik%20Cha",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Seong Hyun Kim",
"url": "https://questionsmedicales.fr/author/Seong%20Hyun%20Kim",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Dan Song",
"url": "https://questionsmedicales.fr/author/Dan%20Song",
"affiliation": {
"@type": "Organization",
"name": "Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review.",
"datePublished": "2023-03-18",
"url": "https://questionsmedicales.fr/article/36933112",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10620-023-07862-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis.",
"datePublished": "2022-11-02",
"url": "https://questionsmedicales.fr/article/36324251",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/apt.17251"
}
},
{
"@type": "ScholarlyArticle",
"name": "Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts.",
"datePublished": "2023-12-17",
"url": "https://questionsmedicales.fr/article/38109970",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jcmgh.2023.12.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact on follow-up strategies in patients with primary sclerosing cholangitis.",
"datePublished": "2022-05-16",
"url": "https://questionsmedicales.fr/article/35535655",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/liv.15286"
}
},
{
"@type": "ScholarlyArticle",
"name": "Anti-integrin αvβ6 autoantibodies in patients with primary sclerosing cholangitis.",
"datePublished": "2023-06-13",
"url": "https://questionsmedicales.fr/article/37310456",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00535-023-02006-6"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012140"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012142"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du poumon",
"item": "https://questionsmedicales.fr/mesh/D008175"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hémangiome sclérosant du poumon",
"item": "https://questionsmedicales.fr/mesh/D047868"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hémangiome sclérosant du poumon - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hémangiome sclérosant du poumon",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hémangiome sclérosant du poumon",
"description": "Comment diagnostique-t-on un hémangiome sclérosant du poumon ?\nQuels examens sont recommandés pour confirmer le diagnostic ?\nLes symptômes influencent-ils le diagnostic ?\nPeut-on confondre cette tumeur avec d'autres lésions ?\nQuel rôle joue la biopsie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Cholangitis,+Sclerosing&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hémangiome sclérosant du poumon",
"description": "Quels sont les symptômes courants de l'hémangiome sclérosant ?\nL'hémangiome sclérosant cause-t-il des difficultés respiratoires ?\nPeut-on avoir des symptômes sans lésion visible ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Cholangitis,+Sclerosing&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hémangiome sclérosant du poumon",
"description": "Peut-on prévenir l'hémangiome sclérosant du poumon ?\nY a-t-il des facteurs de risque connus ?\nLes habitudes de vie influencent-elles le risque ?\nLes examens réguliers aident-ils à la détection précoce ?\nLes femmes sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Cholangitis,+Sclerosing&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hémangiome sclérosant du poumon",
"description": "Quel est le traitement standard pour l'hémangiome sclérosant ?\nPeut-on traiter cette condition par des médicaments ?\nQuand est-il nécessaire de surveiller sans traiter ?\nQuels sont les risques associés à la chirurgie ?\nY a-t-il des traitements alternatifs ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Cholangitis,+Sclerosing&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hémangiome sclérosant du poumon",
"description": "Quelles complications peuvent survenir ?\nL'hémangiome peut-il se transformer en cancer ?\nComment gérer les complications respiratoires ?\nLes complications sont-elles fréquentes ?\nY a-t-il des complications post-chirurgicales ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Cholangitis,+Sclerosing&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hémangiome sclérosant du poumon",
"description": "Quels sont les principaux facteurs de risque ?\nL'exposition à des toxines augmente-t-elle le risque ?\nLes antécédents médicaux influencent-ils le risque ?\nLe tabagisme est-il un facteur de risque ?\nLes facteurs génétiques jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Cholangitis,+Sclerosing&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un hémangiome sclérosant du poumon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie, notamment la tomodensitométrie (TDM) et la biopsie."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "La TDM thoracique et l'IRM peuvent aider à visualiser la lésion et son caractère bénin."
}
},
{
"@type": "Question",
"name": "Les symptômes influencent-ils le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent être absents, rendant le diagnostic souvent incident lors d'examens pour d'autres raisons."
}
},
{
"@type": "Question",
"name": "Peut-on confondre cette tumeur avec d'autres lésions ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres tumeurs pulmonaires, nécessitant une analyse approfondie."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet de confirmer la nature bénigne de la lésion et d'exclure d'autres pathologies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de l'hémangiome sclérosant ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, il peut provoquer une toux ou des douleurs thoraciques dans certains cas."
}
},
{
"@type": "Question",
"name": "L'hémangiome sclérosant cause-t-il des difficultés respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais des complications peuvent entraîner des difficultés respiratoires dans certains cas."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans lésion visible ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes peuvent survenir sans lésion visible, rendant le diagnostic plus complexe."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes ne varient pas significativement selon l'âge, car la plupart des cas sont asymptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez la toux persistante ou des douleurs thoraciques, bien que souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'hémangiome sclérosant du poumon ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de mesures préventives spécifiques pour cette condition bénigne."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque connus ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque ne sont pas clairement établis, mais des antécédents familiaux peuvent jouer un rôle."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve directe ne lie les habitudes de vie au développement de l'hémangiome sclérosant."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à la détection précoce ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers peuvent aider à détecter des anomalies, mais l'hémangiome est souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent une prévalence plus élevée chez les femmes, mais les données sont limitées."
}
},
{
"@type": "Question",
"name": "Quel est le traitement standard pour l'hémangiome sclérosant ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est généralement chirurgical si la tumeur est symptomatique ou suspecte."
}
},
{
"@type": "Question",
"name": "Peut-on traiter cette condition par des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement médicamenteux spécifique, la chirurgie est la principale option."
}
},
{
"@type": "Question",
"name": "Quand est-il nécessaire de surveiller sans traiter ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Si la tumeur est asymptomatique et bénigne, une surveillance régulière peut suffire."
}
},
{
"@type": "Question",
"name": "Quels sont les risques associés à la chirurgie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections, des saignements et des complications respiratoires post-opératoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements alternatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements alternatifs ne sont pas prouvés efficaces et ne remplacent pas la chirurgie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections pulmonaires et des hémorragies dans de rares cas."
}
},
{
"@type": "Question",
"name": "L'hémangiome peut-il se transformer en cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'hémangiome sclérosant est une tumeur bénigne et ne se transforme pas en cancer."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications respiratoires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications respiratoires doivent être traitées symptomatiquement et surveillées attentivement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares, la plupart des cas étant asymptomatiques et sans incidents."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications post-chirurgicales ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme des infections ou des saignements peuvent survenir après la chirurgie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque ne sont pas bien définis, mais des antécédents familiaux peuvent être impliqués."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines augmente-t-elle le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve solide ne lie l'exposition à des toxines au développement de l'hémangiome sclérosant."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents médicaux ne semblent pas avoir d'impact direct sur le développement de cette tumeur."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le lien entre tabagisme et hémangiome sclérosant n'est pas clairement établi dans la littérature."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que des facteurs génétiques peuvent influencer le développement de l'hémangiome."
}
}
]
}
]
}
We conducted a systematic literature review to understand the evidence supporting treatment decisions for cholestatic pruritus associated with primary biliary cholangitis (PBC) and primary sclerosing ...
Studies that enrolled ≥ 75% participants with PBC or PSC and reported ≥ 1 endpoint(s) related to efficacy, safety, health-related quality of life (HRQoL) or other patient-reported outcomes were includ...
Thirty-nine publications were identified, covering 42 studies and six treatment classes (including investigational and approved products): anion-exchange resins, antibiotics (rifampicin/derivatives), ...
There is a lack of consistent and reproducible evidence available on efficacy, impact on HRQoL, and safety of cholestatic pruritus treatments, leaving physicians to rely on clinical experience rather ...
Primary sclerosing cholangitis (PSC) is a progressive liver disease with poor prognosis and no effective therapies to prevent progression. An aetiopathological link between PSC and gastrointestinal mi...
To evaluate all potential medical therapies which may exert their effect in PSC by modulation of the gut-liver axis....
We conducted a comprehensive scoping review of PubMed and Cochrane Library, including all articles evaluating an intervention aimed at manipulating the gastrointestinal microbiome in PSC....
A wide range of therapies proposed altering the gastrointestinal microbiome for the treatment of PSC. In particular, these considered antibiotics including vancomycin, metronidazole, rifaximin, minocy...
The gut-liver axis is increasingly considered a potential target for the treatment of PSC. However, no therapies have been demonstrated to improve transplant-free survival. Innovative and well-designe...
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with progressive biliary inflammation, destruction of the biliary tract, and fibrosis, resulting in liver cirrhosis and end-sta...
Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies i...
We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or ...
A broad variety of different follow-up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endosco...
Follow-up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and incr...
Patients with primary sclerosing cholangitis (PSC) possess autoantibodies against biliary epithelial cells. However, the target molecules remain unknown....
The sera of patients with PSC and controls were subjected to enzyme-linked immunosorbent assays to detect autoantibodies using recombinant integrin proteins. Integrin αvβ6 expression in the bile duct ...
Anti-integrin αvβ6 antibodies were detected in 49/55 (89.1%) patients with PSC and 5/150 (3.3%) controls (P < 0.001), with a sensitivity and specificity of 89.1% and 96.7%, respectively, for PSC diagn...
Autoantibodies against integrin αvβ6 were detected in most patients with PSC; anti-integrin αvβ6 antibody may serve as a potential diagnostic biomarker for PSC....
Sclerosing cholangitis comprises a group of conditions that lead to chronic cholestatic disease of the bile ducts, characterized by inflammation, fibrosis, and segmental strictures of the intrahepatic...
The epigenome, the set of modifications to DNA and associated molecules that control gene expression, cellular identity, and function, plays a major role in mediating cellular responses to outside fac...
We performed epigenome-wide association studies of primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) using the Illumina MethylationEPIC Bead Chip....
We found evidence of increased epigenetic age acceleration and differences in predicted immune cell composition in patients with PSC and PBC. Epigenetic profiles demonstrated differences in predicted ...
This study provides insights into methylation profiles of patients that support current concepts of disease mechanisms and provide novel data to inspire future research. Studies to corroborate our fin...
The prevalence of primary sclerosing cholangitis (PSC) in the general population has not yet been clearly established. The management of PSC should focus on delaying the progression of the disease and...
Our objective is to evaluate the indications and outcomes of PSC patients undergoing LT in three liver transplantation centers in southern Brazil - Hospital Santa Isabel in Blumenau, Santa Catarina st...
This is a longitudinal observational study of patients with PSC who underwent LT in three major Brazilian medical centers. Electronic medical records and study protocols of all patients subjected to L...
Of the 1,362 transplants performed in the three medical centers, 37 were due to PSC. Recurrence of PSC occurred in three patients (8.1%) in 3.0±2.4 years (range, 1-4 years). The 1-year and 5-year surv...
Our experience with LT in patients with PSC demonstrated good patient and graft survival results. Most deaths were due to common factors in patients undergoing LT....
The evidence for hepatobiliary tumour surveillance in patients with primary sclerosing cholangitis (PSC) is scarce. In this study, we aimed to prospectively evaluate cholangiocarcinoma (CCA) surveilla...
In total, 512 patients with PSC from 11 Swedish hospitals were recruited. The study protocol included yearly clinical follow-ups, liver function tests and contrast-enhanced MRI/MRCP and carbohydrate a...
Eleven patients (2%) were diagnosed with CCA, and two (0.5%) with high-grade bile duct dysplasia. Severe/progressive bile duct changes on MRI/MRCP were detected in 122 patients (24%), of whom 10% had ...
In an unselected cohort of patients with PSC, yearly CA19-9 and MRI/MRCP surveillance followed by ERCP was ineffective in detecting cancer early enough to support long-term survival. Given the low occ...
A prospective nationwide 5-year study was conducted to evaluate yearly cholangiocarcinoma surveillance using MRI and CA19-9 in patients with primary sclerosing cholangitis. Only 2% of the patients wer...
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are 2 major liver autoimmune diseases. PBC is common in women and primarily affects intrahepatic small bile duct epithelial c...